


## Semi-synthetic O25B-CRM197 conjugate vaccines give rise to functional antibodies in murine model

Max BARTETZKO [1], Arun NAINI [1], Someswara RAO SANAPALA [3], Felix BROECKER [1], Victoria WIRTZ, Marilda P. LISBOA, Sharavathi G. PARAMESWARAPPA [1], Daniel KNOPP [1], Jessica PRZYGODDA [1], Matthias HAKELBERG [1], Rosalind PAN [2], Axay PATEL [2], Laurent CHORRO [2], Arthur ILLENBERGER [2], Christopher PONCE [2], Srinivas KODALI [2], Jacqueline LYPOWY [2], Annaliesa S. ANDERSON [2], Arne VON BONIN [1], Robert G. K. DONALD [2], Clancy L. PEREIRA [1]

[1] Idorsia (Berlin) Pharmaceuticals GmbH GERMANY, [2] Pfizer Vaccine Research and Development, Pearl River, New York 10965, UNITED STATES, [3] Indian Institute of Technology Tirupati, Yerpedu, Tirupati 517619, Andhra Pradesh, INDIA

max.bartetzko@idorsia.com

Pathogenic, multidrug resistant *E. Coli* strains causing enteric/diarrheal, urinary tract infections, sepsis and meningitis are of increasing concern worldwide. A major serotype of extraintestinal pathogenic *E. Coli* (ExPEC) is O25B, expressing an unique *O*-antigen consisting of a branched five monosaccharide repeating unit. The chemical synthesis of five fragments of various length or frameshift oligosaccharides gave access to a set of well-defined semi-synthetic glycoconjugate vaccine candidates targeting the *O*-antigen of *E. Coli* O25B serotype. The semi-synthetic glycoconjugate vaccines induced similar levels of functional IgG antibodies with opsonophagocytic activity against *E. Coli* O25B in mice as the conventional polysaccharide vaccine candidate prepared with native O25B *O*-antigen. Furthermore, it was shown that our synthetic O25B antigens can give rise to antibodies with nanomolar affinity. Moreover, we found that acetylation of a rhamnose residue as it occurs in the natural polysaccharide most likely does not influence the immunogenicity of the antigens as also our deacetylated antigen elicited a strong functional IgG response. Overall, the direct comparison of the immunogenicity of a glycoconjugate vaccine prepared with isolated *O*-antigen to those prepared with chemically synthesized *O*-antigens allows a more comprehensive analysis of the binding epitopes and lays foundation for rationally designed chemically synthesized oligosaccharide-based vaccines.



### Bibliographic references:

A. Naini, M. P. Bartetzko, S. R. Sanapala, F. Broecker, V. Wirtz, M. P. Lisboa, S. G. Parameswarappa, D. Knopp, J. Przygodda, M. Hakelberg, R. Pan, A. Patel, L. Chorro, A. Illenberger, C. Ponce, S. Kodali, J. Lypowy, A. S. Anderson, R. G. K. Donald, A. von Bonin, C. L. Pereira (2022) *JACS Au* (9), 2135-2151